Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Rigel Pharmaceuticals revenue
Rigel Pharmaceuticals's revenue is $179.3 million.
What is Rigel Pharmaceuticals's revenue?
- Rigel Pharmaceuticals's revenue growth from 2010 to 2024 is 43.42%.
- Rigel Pharmaceuticals has 158 employees, and the revenue per employee ratio is $1,134,670.
- Rigel Pharmaceuticals's peak quarterly revenue was $81.0M in 2021(q1).
- Rigel Pharmaceuticals peak revenue was $179.3M in 2024.
- Rigel Pharmaceuticals annual revenue for 2023 was 116.9M, -2.79% growth from 2022.
- Rigel Pharmaceuticals annual revenue for 2024 was 179.3M, 53.38% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Rigel Pharmaceuticals historical revenue
Rigel Pharmaceuticals's peak revenue was $179.3M in 2024. The peak quarterly revenue was $81.0M in 2021(q1).
Rigel Pharmaceuticals's revenue increased from $125.0m in 2010 to $179.3M currently. That's a 43.42% change in annual revenue.
Rigel Pharmaceuticals annual revenue
Rigel Pharmaceuticals annual revenue over time
| Fiscal year / year | Rigel Pharmaceuticals revenue |
|---|---|
| 2010 | $125.0M |
| 2011 | $4.8M |
| 2012 | $2.3M |
| 2013 | $7.2M |
| 2014 | $8.3M |
| 2015 | $28.9M |
| 2016 | $20.4M |
| 2017 | $4.5M |
| 2018 | $44.5M |
| 2019 | $59.3M |
| 2020 | $108.6M |
| 2021 | $149.2M |
| 2022 | $120.2M |
| 2023 | $116.9M |
| 2024 | $179.3M |
Rate Rigel Pharmaceuticals' financial transparency
Rigel Pharmaceuticals annual growth
Rigel Pharmaceuticals saw the greatest revenue growth in 2018, when revenue increased by 892.62%.
Rigel Pharmaceuticals had the lowest revenue growth in 2011, when revenue changed by -96.2%.
Rigel Pharmaceuticals annual growth rate over time
| Year | Rigel Pharmaceuticals growth |
|---|---|
| 2011 | -96%↓ |
| 2012 | -53%↓ |
| 2013 | 218%↑ |
| 2014 | 15%↑ |
| 2015 | 250%↑ |
| 2016 | -29%↓ |
| 2017 | -78%↓ |
| 2018 | 893%↑ |
| 2019 | 33%↑ |
| 2020 | 83%↑ |
| 2021 | 37%↑ |
| 2022 | -19%↓ |
| 2023 | -3%↓ |
| 2024 | 53%↑ |
Rigel Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Rigel Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | $395,000 | $4.4M | - |
| 2012 | $750,000 | $1.5M | - | - |
| 2013 | - | $1.4M | - | $5.8M |
| 2015 | $2.2M | $5.2M | $13.0M | $8.5M |
| 2016 | $5.0M | $8.6M | $3.8M | $3.0M |
| 2017 | $3.6M | - | $900,000 | - |
| 2018 | - | $1.8M | $4.9M | $37.9M |
| 2019 | $12.6M | $10.4M | $20.9M | $15.4M |
| 2020 | $55.8M | $16.0M | $18.4M | $18.5M |
| 2021 | $81.0M | $26.3M | $21.5M | $20.4M |
| 2022 | $16.7M | $29.8M | $22.4M | $51.3M |
| 2023 | $26.1M | $26.9M | $28.1M | $35.8M |
| 2024 | $29.5M | $36.8M | $55.3M | $57.6M |
Rigel Pharmaceuticals jobs nearby
Do you work at Rigel Pharmaceuticals?
Is Rigel Pharmaceuticals transparent about its revenue structure?
Rigel Pharmaceuticals financial information
| CEO | Mr. George B. Kauffman |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 158 |
| Date Founded | 1996 |
| Headquarters | South San Francisco, California |
| Number of Locations | 2 |
| Revenue | $179.3M |
| Net Income | -$58,573,000 |
| Gross Proft | $160.6M (2024) |
| PE Ratio | 25.75 |
| Tax Rate | 0.0% |
| Market Capitalization | $450.3M |
| Total Assets | $134,279,000 |
| Ticker | RIGL |
Rigel Pharmaceuticals jobs you might like
Rigel Pharmaceuticals financing
Rigel Pharmaceuticals received early financing of $46.0M on 2003-04-30.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $46M | 04/2003 |
| Post Ipo Equity | $130M | 05/2011 |
| Grant | $16.5M | 01/2021 |
Rigel Pharmaceuticals investors
| Investors | Security type |
|---|---|
| HBM Healthcare Investments AG | Post Ipo Equity |
| MPM Capital | Post Ipo Equity |
| Frazier Healthcare Partners | Post Ipo Equity |
| Alta Partners | Post Ipo Equity |
| US Department Of Defense | Grant |
Rigel Pharmaceuticals competitors
Rigel Pharmaceuticals's top competitor, Regeneron, earned an annual revenue of $14.2B.
Rigel Pharmaceuticals's smallest competitor is Arena Pharmaceuticals with revenue of $54.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Theravance Biopharma | $75,498 | $64.4M | 363 | 1 |
| Regeneron | $85,589 | $14.2B | 9,123 | 397 |
| Genentech | $97,473 | $166.9M | 13,638 | 546 |
| Pharmacyclics | $97,383 | $235.0M | 607 | - |
| Arena Pharmaceuticals | $78,517 | $54,000 | 194 | - |
| Crown Bioscience | $78,956 | $12.0M | 350 | 7 |
| Senomyx | $51,255 | $26.4M | 56 | - |
| Array BioPharma | $90,967 | $173.8M | 298 | - |
| aTyr Pharma | $50,059 | $235,000 | 44 | - |
| Neurocrine Biosciences | $78,232 | $2.4B | 400 | 395 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Rigel Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Rigel Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Rigel Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Rigel Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Rigel Pharmaceuticals. The data presented on this page does not represent the view of Rigel Pharmaceuticals and its employees or that of Zippia.
Rigel Pharmaceuticals may also be known as or be related to RIGEL PHARMACEUTICALS INC, Rigel Pharmaceuticals, Rigel Pharmaceuticals Inc, Rigel Pharmaceuticals Inc. and Rigel Pharmaceuticals, Inc.